Last reviewed · How we verify
A Study of JNJ-70075200 in Healthy Participants
The purpose of the study is to evaluate safety and tolerability of JNJ-70075200 compared with placebo after administration of single ascending doses of JNJ-70075200 as oral solution (Part 1); multiple ascending doses of JNJ-70075200, administered as oral solution over 14 consecutive days (Part 2); and the option of a single dose of JNJ-70075200 administered as an oral solid formulation (Part 3).
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1 |
| Status | WITHDRAWN |
| Start date | Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Sep 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- JNJ-70075200
- Placebo
Countries
Netherlands